European regulators greenlight Fractyl Health's clinical test of GLP-1 gene therapy

Fractyl Health has received approval from European regulators to conduct clinical tests on its innovative GLP-1 gene therapy, which aims to provide a long-lasting alternative to chronic injections and pills. This development is part of a broader trend among drug developers seeking to revolutionize treatment options for patients with metabolic conditions. If successful, this therapy could significantly change the landscape of diabetes management.